Literature DB >> 8491762

Immuno-biochemical assay for determination of nuclear steroid receptors during tamoxifen therapy.

A Vering1, A Vockel, M Stegmüller, H G Bender.   

Abstract

The exact knowledge of hormone receptor status is critical for therapeutic strategies in hormone-dependent tumors. The influence of tamoxifen on estrogen receptor concentration has to be taken into account when evaluating results in tamoxifen-treated patients. We studied the receptor modulation of tumors xenotransplanted into nude mice (one breast and one endometrial carcinoma) after injection of 50 micrograms tamoxifen/mouse. To differentiate between unoccupied and occupied receptors, determinations were done by an enzyme immunoassay for the estrogen receptor under low- and high-salt extraction. With low-salt extraction we found a temporary decrease of the estrogen receptor concentration within the first hours after tamoxifen treatment. This decrease lasted for several days before recovery to pretreatment levels occurred. The hormone-receptor complexes, tightly bound to acceptor sites of the DNA, increased more than 15 times within 24 h. These values remained at increased levels for 2-7 days, after which a decrease to initial level was observed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491762     DOI: 10.1007/BF01218423

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  34 in total

1.  Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat.

Authors:  V C Jordan; C J Dix; L Rowsby; G Prestwich
Journal:  Mol Cell Endocrinol       Date:  1977-04       Impact factor: 4.102

2.  Standards for the assessment of estrogen receptors in human breast cancer. Report of a workshop on September 29, 1972, at the Antoni van Leeuwenhoek-Huis, Amsterdam.

Authors: 
Journal:  Eur J Cancer       Date:  1973-05       Impact factor: 9.162

3.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

4.  Effects of oestradiol-17beta and tamoxifen on nuclear oestradiol-17beta receptors in DMBA-induced rat mammary tumours.

Authors:  R I Nicholson; P Davies; K Griffiths
Journal:  Eur J Cancer       Date:  1977-03-29       Impact factor: 9.162

5.  Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing.

Authors:  K B Horwitz; W L McGuire
Journal:  J Biol Chem       Date:  1978-11-25       Impact factor: 5.157

6.  Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor.

Authors:  K B Horwitz; W L McGuire
Journal:  J Biol Chem       Date:  1978-04-10       Impact factor: 5.157

7.  Determination of estrogen receptor in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States.

Authors:  V C Jordan; H I Jacobson; E J Keenan
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

8.  Progesterone and estrogen receptors as prognostic variables in breast cancer.

Authors:  B H Mason; I M Holdaway; P R Mullins; L H Yee; R G Kay
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

Review 9.  Progesterone receptors and human breast cancer.

Authors:  G M Clark; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

10.  Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.

Authors:  G M Clark; C K Osborne; W L McGuire
Journal:  J Clin Oncol       Date:  1984-10       Impact factor: 44.544

View more
  1 in total

1.  Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.

Authors:  I Soubeyran; N Quénel; L Mauriac; M Durand; F Bonichon
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.